phenserine has been researched along with physostigmine in 75 studies
| Studies (phenserine) | Trials (phenserine) | Recent Studies (post-2010) (phenserine) | Studies (physostigmine) | Trials (physostigmine) | Recent Studies (post-2010) (physostigmine) |
|---|---|---|---|---|---|
| 88 | 6 | 39 | 6,230 | 252 | 331 |
| Protein | Taxonomy | phenserine (IC50) | physostigmine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.1666 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.3023 | |
| Cholinesterase | Homo sapiens (human) | 0.3055 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.2 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.0269 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.0853 | |
| Acetylcholinesterase | Bos taurus (cattle) | 0.7197 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 1.1821 | |
| Acetylcholinesterase | Gallus gallus (chicken) | 0.02 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.0416 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Cholinesterase | Equus caballus (horse) | 0.4081 | |
| Cholinesterase | Mus musculus (house mouse) | 0.28 | |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 0.0189 | |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 0.018 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 1.263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (13.33) | 18.2507 |
| 2000's | 31 (41.33) | 29.6817 |
| 2010's | 29 (38.67) | 24.3611 |
| 2020's | 5 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brossi, A | 1 |
| Brossi, A; Flippen-Anderson, JL; Greig, NH; Hoffman, B; Holloway, HW; Yu, Q | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Whittaker, NF; Yu, QS; Zhu, X | 1 |
| Alley, GM; Brossi, A; Deschamps, JR; Greig, NH; Holloway, HW; Kulkarni, SS; Lahiri, DK; Luo, W; Parrish, D; Yu, QS; Zhan, M | 1 |
| Duncton, MA; Emerling, DE; Kelly, MG; Nguyen, MT; Vincent, F | 1 |
| Bian, HL; Shan, WG; Wang, JW; Zhan, ZJ | 1 |
| Chaudhaery, SS; Nath, C; Nazir, A; Roy, KK; Sammi, SR; Saxena, AK; Saxena, G; Shakya, N | 1 |
| Li, J; Liu, D; Liu, W; Shi, T; Wang, D; Wang, Y; Wang, Z; Yin, G; Zhang, H | 1 |
| Li, X; Wang, S; Wang, Y; Wang, Z; Zhang, H | 1 |
| Brossi, A; Greig, NH; Ikari, H; Ingram, DK; Patel, N; Pei, XF; Spangler, EL; Speer, D | 1 |
| Brossi, A; Garofalo, P; Greig, NH; Heller, B; Iijima, S; Ingram, DK; Spangler, EL | 1 |
| Brossi, A; Greig, NH; Ingram, DK; Pei, XF; Soncrant, TT | 1 |
| Acevedo, LD; Davis, KL; Gluck, R; Greig, N; Haroutunian, V; Pei, XF; Utsuki, T; Wallace, WC | 1 |
| Greig, NH; Ingram, DK; Meyer, RC; Patel, N; Spangler, EL; Yu, QS | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Yu, Q | 1 |
| al-Jafari, AA; Alhomida, AS; Greig, NH; Kamal, MA; Perry, ER | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Utsuki, T; Yu, Q | 1 |
| Kilbourn, MR; Sherman, PS; Snyder, SE | 1 |
| Al-Jafari, AA; Alhomida, AS; Greig, NH; Kamal, MA | 1 |
| Kilbourn, MR; Sherman, PS; Skaddan, MB; Snyder, SE | 1 |
| Brossi, A; De Micheli, E; Deutsch, J; Greig, NH; Holloway, HW; Ingram, DK; Lahiri, DK; Perry, TA; Soncrant, TT; Utsuki, T; Yu, QS | 1 |
| Brossi, A; Ge, YW; Greig, NH; Lahiri, DK; Rogers, J; Sambamurti, K; Shaw, KT; Utsuki, T; Yu, QS | 1 |
| Jewett, DM; Kilbourn, MR; Sherman, PS; Skaddan, MB | 1 |
| Kilbourn, MR; Koeppe, RA; Ma, B; Moskwa, JE; Sherman, PS | 1 |
| Huang, A; Kodanko, JJ; Overman, LE | 1 |
| Cunningham, SC; Devan, BD; Duffy, KB; Greig, NH; Holloway, HW; Ingram, DK; Janas, AM; Markowska, AL; Spangler, EL; Yu, QS | 1 |
| Bush, AI; Eder, P; Giordano, T; Greig, NH; Lahiri, DK; Rogers, JT; Venti, A | 1 |
| Araujo, JA; Milgram, NW; Studzinski, CM | 1 |
| Brossi, A; Bruinsma, GB; Greig, NH; Lahiri, DK; Sambamurti, K; Yu, QS | 1 |
| Thatte, U | 1 |
| Brownell, L; Burford, RG; Canfield, CJ; Comer, P; Flanagan, DR; Greig, NH; Holloway, HW; Ruckle, J | 1 |
| Castro, A; Martinez, A | 1 |
| Quancard, J; Trost, BM | 1 |
| Brossi, A; Chen, D; Davidson, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Klein, P; Li, Y; Tweedie, D; Yu, QS | 1 |
| Chen, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Maloney, B; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Greig, NH; Holloway, HW; Ingram, DK; Irie, T; Irikura, M; Mamczarz, J; Moriuchi, H; Spangler, EL; Uchimura, N; Utsuki, T; Yu, QS | 1 |
| Rigby, JH; Sidique, S | 1 |
| Klein, J | 1 |
| Alley, GM; Chen, D; Greig, NH; Lahiri, DK; Tweedie, D | 1 |
| Greig, NH; Marutle, A; Nilbratt, M; Nordberg, A; Ohmitsu, M; Sugaya, K | 1 |
| Almkvist, O; Andreasen, N; Blennow, K; Engler, H; Forsberg, A; Hagman, G; Kadir, A; Långström, B; Lärksäter, M; Nordberg, A; Wall, A; Winblad, B; Zetterberg, H | 1 |
| Barak, D; Greig, NH; Ordentlich, A; Shafferman, A; Stein, D; Yu, QS | 1 |
| Merchant, S; Sugaya, K | 1 |
| Lahiri, DK; Schneider, LS | 1 |
| Becker, RE; Bruinsma, G; Friedhoff, LT; Frölich, L; Giacobini, E; Greig, NH; Winblad, B | 1 |
| Trost, BM; Zhang, Y | 1 |
| Araujo, JA; de Rivera, C; Greig, NH; Ingram, DK; Milgram, NW; Sandin, J | 1 |
| Hong, E; Liy-Salmeron, G; Meneses, A; Ponce-Lopez, T | 1 |
| Chiou, G; Garg, NK; Schammel, AW | 1 |
| Cardinale, KM; Greig, NH; Hsu, M; Manji, HK; Martinowich, K; Schloesser, RJ | 1 |
| Becker, RE; Greig, NH | 2 |
| Garcia, CC; Hognason, K; McArdle, JJ; Potian, JG; Routh, VH; Souayah, N; Sultatos, LG; Thyagarajan, B | 1 |
| Chang, MY; Greig, NH; John, V; Maccecchini, ML; Pan, C; Zetterberg, H | 1 |
| Higuchi, K; Kawasaki, T; Matsumoto, K; Narumi, F; Osada, Y; Satoh, M; Shinada, M; Tanaka, H; Yoshida, T | 1 |
| Reale, M; Tata, AM | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Lahiri, DK; Luo, W; Ray, B; Reale, M; Rogers, JT; Sambamurti, K; Yu, QS | 1 |
| Greig, NH; Li, Y; Lilja, AM; Luo, Y; Marini, AM; Marutle, A; Nordberg, A; Röjdner, J; Yu, QS | 1 |
| Gonzalez, D; Greig, NH; Lilja, AM; Marutle, A; Mustafiz, T; Nordberg, A; Röjdner, J; Storelli, E; Thomé, CM; Unger-Lithner, C | 1 |
| Balleidier, A; Bandyopadhyay, S; Cahill, C; Huang, C; Huang, X; Lahiri, DK; Rogers, JT | 1 |
| Darreh-Shori, T; Hosseini, SM; Nordberg, A | 1 |
| Chen, C; Chen, J; Greig, NH; He, J; Iskandar, K; Jacobowitz, DM; Marini, AM; McDonough, JH; Pan, H; Piermartiri, T; Wu, W; Yu, QS | 1 |
| Lilja, AM; Malmsten, L; Marutle, A; Nordberg, A; Ögren, SO; Röjdner, J; Verkhratsky, A; Voytenko, L | 1 |
| Almkvist, O; Andreasen, N; Kadir, A; Långström, B; Nordberg, A; Wall, A; Zetterberg, H | 1 |
| Barak, S; Becker, KG; Becker, RE; Fukui, K; Greig, NH; Hoffer, BJ; Holloway, HW; Lehrmann, E; Li, Y; Luo, Y; Perez, E; Pick, CG; Rubovitch, V; Tamargo, IA; Tweedie, D; Van Praag, H; Wood, WH; Yu, QS; Zhang, Y | 1 |
| Becker, RE; Chiang, YH; Greig, NH; Hoffer, BJ; Hoffer, ME; Pick, CG | 1 |
| Becker, RE; Chang, CF; Chen, KY; Chen, YH; Chiang, YH; Greig, NH; Kang, SJ; Lai, JH; Luo, Y; Wu, JC | 1 |
| Aarsland, D; Ballard, C; Becker, RE; Bledsoe, J; Ferrucci, L; Flanagan, D; Govindarajan, R; Greig, NH; Kapogiannis, D; Lahiri, DK; Majercik, S; Sano, M; Schneider, LS | 1 |
| Barnett, A; Casey, A; Greig, NH; Jin, Y; Kim, P; Luo, Y; Scerba, M; Selman, W; Turcato, F | 1 |
| Damanhouri, GA; Tabrez, S | 1 |
| Bader, M; Becker, RE; Greig, NH; Hoffer, BJ; Hoffman, AF; Hsueh, SC; Jung, YJ; Lecca, D; Lupica, CR; Pick, CG; Tweedie, D | 1 |
| Becker, RE; Chiang, YH; Glotfelty, EJ; Greig, NH; Hoffer, BJ; Hsueh, SC; Kapogiannis, D; Lecca, D; Nogueras-Ortiz, C; Tweedie, D | 1 |
| Chen, XQ; Kleschevnikov, AM; Maccecchini, M; Mobley, WC; Nguyen, PD; Overk, C; Pearn, ML; Salehi, A | 1 |
| Greven, NJ; Hiller, W; Kaiser, M; Kruth, S; Nett, M; Pietruszka, J; Schneider, P; Winand, L | 1 |
12 review(s) available for phenserine and physostigmine
| Article | Year |
|---|---|
Alfred Burger award address. Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine.
Topics: Animals; Chemical Phenomena; Chemistry; Colchicine; Humans; Physostigmine | 1990 |
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Ligands | 2022 |
Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Rats; Structure-Activity Relationship | 1995 |
Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
Topics: Acetylcholine; Aging; Animals; Cognition Disorders; Dementia; Disease Models, Animal; Dogs; Humans; Physostigmine; Scopolamine | 2005 |
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Tartrates | 2005 |
Phenserine Axonyx.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Molecular Structure; Physostigmine | 2005 |
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Galantamine; Humans; Physostigmine; Protein Conformation | 2006 |
Phenserine.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Mice; Physostigmine; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2007 |
How to approach Alzheimer's disease therapy using stem cell technologies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Differentiation; Cell Proliferation; Cholinesterase Inhibitors; Cognition; Humans; Mice; Neurons; Physostigmine; Rats; Stem Cell Transplantation; Stem Cells | 2008 |
Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Cholinesterase Inhibitors; Drug Repositioning; Humans; Mice; Physostigmine; Psychotropic Drugs; Rats | 2017 |
(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cell Death; Cholinesterase Inhibitors; Humans; Physostigmine | 2018 |
(-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Cell Survival; Humans; Mice; Mice, Transgenic; Neuroprotective Agents; Physostigmine; Tartrates; Treatment Outcome | 2020 |
6 trial(s) available for phenserine and physostigmine
| Article | Year |
|---|---|
Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.
Topics: Acetylcholinesterase; Aged; Area Under Curve; Cholinesterase Inhibitors; Erythrocytes; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Physostigmine | 2005 |
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid; Brain; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Physostigmine; Placebo Effect; Positron-Emission Tomography; Treatment Outcome | 2008 |
Phenserine efficacy in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Treatment Outcome | 2010 |
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognitive Dysfunction; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation Mediators; Male; Peptide Fragments; Physostigmine; Rats; Rats, Inbred F344; tau Proteins | 2012 |
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Blotting, Western; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Drug Therapy, Combination; Fluorescence; Follow-Up Studies; Humans; Indans; Physostigmine; Piperidines; Thiazoles; Time Factors | 2014 |
Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Brain; Cognition; Double-Blind Method; Female; Glucose; Humans; Male; Nootropic Agents; Peptide Fragments; Phosphorylation; Physostigmine; Positron-Emission Tomography; tau Proteins; Time Factors; Treatment Outcome | 2015 |
57 other study(ies) available for phenserine and physostigmine
| Article | Year |
|---|---|
Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Erythrocytes; Humans; Models, Molecular; Molecular Conformation; Physostigmine; Structure-Activity Relationship | 2001 |
Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
Topics: Acetylcholinesterase; Alkaloids; Butyrylcholinesterase; Cholinesterase Inhibitors; Cyclic N-Oxides; Humans; Isomerism; Oxazines; Structure-Activity Relationship | 2002 |
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
Topics: Acetylcholinesterase; Amyloid beta-Protein Precursor; Benzofurans; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Neurons; Oxepins; Structure-Activity Relationship | 2005 |
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Topics: Amidohydrolases; Carbamates; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2009 |
Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Indoles; Neurotransmitter Agents; Physostigmine; Rats; Structure-Activity Relationship | 2010 |
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Topics: Acetylcholinesterase; Administration, Oral; Animals; Avoidance Learning; Caenorhabditis elegans; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Databases, Factual; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Nootropic Agents; Quantitative Structure-Activity Relationship; Scopolamine | 2010 |
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Drug Design; Humans; Male; Maze Learning; Molecular Docking Simulation; Neuroprotective Agents; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tryptamines | 2022 |
Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase.
Topics: Aging; Animals; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Male; Maze Learning; Memory; Physostigmine; Rats; Rats, Inbred F344 | 1995 |
Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Cholinesterase Inhibitors; Electroshock; Male; Maze Learning; Physostigmine; Rats; Rats, Inbred F344; Scopolamine | 1993 |
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Isoflurophate; Male; Muscarinic Antagonists; Physostigmine; Prosencephalon; Rats; Rats, Sprague-Dawley; Scopolamine | 1997 |
Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor.
Topics: Animals; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Learning Disabilities; Male; Maze Learning; Physostigmine; Piperazines; Rats; Rats, Inbred F344; Receptors, N-Methyl-D-Aspartate | 1998 |
Syntheses and anticholinesterase activities of (3aS)-N1, N8-bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Erythrocytes; Humans; Hydrolysis; In Vitro Techniques; Indoles; Oxidation-Reduction; Phenylcarbamates; Physostigmine; Stereoisomerism; Structure-Activity Relationship | 1998 |
Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.
Topics: Acetylcholinesterase; Acetylthiocholine; Cholinesterase Inhibitors; Erythrocytes; Humans; Kinetics; Male; Physostigmine | 1998 |
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Humans; Physostigmine; Structure-Activity Relationship | 1999 |
Simplified methods for in vivo measurement of acetylcholinesterase activity in rodent brain.
Topics: Acetylcholinesterase; Animals; Brain; Carbon Radioisotopes; Female; Kinetics; Mice; Neostigmine; Physostigmine; Piperidines; Reproducibility of Results; Tissue Distribution | 1999 |
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding, Competitive; Cholinesterase Inhibitors; Humans; Kinetics; Physostigmine | 2000 |
Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors.
Topics: Acetylcholine; Animals; Benzilates; Brain; Cerebellum; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Fluorine Radioisotopes; Hypothalamus; Male; Muscarinic Antagonists; Physostigmine; Piperidines; Rats; Receptors, Muscarinic | 2001 |
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Half-Life; Infusions, Intravenous; Male; Physostigmine; Rats; Rats, Inbred F344; Tacrine | 2000 |
Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development.
Topics: 5' Untranslated Regions; Amyloid beta-Protein Precursor; Astrocytoma; Cell Survival; Chloramphenicol O-Acetyltransferase; Cholinesterase Inhibitors; Chromones; Culture Media, Conditioned; Drug Design; Enzyme Inhibitors; Flavonoids; Gene Expression Regulation; Humans; Interleukin-1; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinases; Morpholines; Neuroblastoma; Phosphatidylinositol 3-Kinases; Physostigmine; Protein Biosynthesis; Recombinant Proteins; RNA, Messenger; Transfection; Tumor Cells, Cultured | 2001 |
(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor.
Topics: Animals; Benzilates; Binding, Competitive; Brain; Carbon Radioisotopes; Cholinesterase Inhibitors; Female; Ligands; Macaca nemestrina; Male; Mice; Mice, Inbred Strains; Physostigmine; Piperidines; Pyrrolidines; Radioactive Tracers; Rats; Receptors, Muscarinic; Tissue Distribution; Tomography, Emission-Computed | 2002 |
Sensitivity of [11C]N-methylpyrrolidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods.
Topics: Acetylcholine; Animals; Benzilates; Brain; Isotope Labeling; Male; Physostigmine; Pyrrolidines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Tomography, Emission-Computed | 2004 |
Asymmetric synthesis of pyrrolidinoindolines. Application for the practical total synthesis of (-)-phenserine.
Topics: Alkylation; Indoles; Physostigmine; Pyrrolidines; Stereoisomerism | 2004 |
The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.
Topics: Animals; Cholinesterase Inhibitors; Male; Maze Learning; Physostigmine; Rats; Rats, Inbred F344; Scopolamine | 2005 |
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
Topics: 5' Untranslated Regions; Amyloid beta-Protein Precursor; Cell Line, Tumor; Cholinesterase Inhibitors; Deferoxamine; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Neuroblastoma; Physostigmine; RNA, Messenger; Siderophores; Transfection | 2004 |
Palladium-catalyzed enantioselective C-3 allylation of 3-substituted-1H-indoles using trialkylboranes.
Topics: Alkenes; Boranes; Catalysis; Indoles; Palladium; Physostigmine; Stereoisomerism | 2006 |
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Extracellular Space; Humans; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Physostigmine; RNA, Messenger; Stereoisomerism; Structure-Activity Relationship | 2006 |
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Physostigmine; Time Factors | 2006 |
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Physostigmine; RNA, Messenger; Stereoisomerism | 2007 |
Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
Topics: Acetylcholinesterase; Administration, Cutaneous; Animals; Avoidance Learning; Butyrylcholinesterase; Cerebral Cortex; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Cognition; Diffusion Chambers, Culture; Electroshock; Excipients; Male; Muscarinic Antagonists; Ointments; Physostigmine; Rats; Rats, Inbred F344; Scopolamine; Skin Absorption | 2007 |
Total synthesis of (+/-) -phenserine via [4+1] cyclization of a bis(alkylthio)carbene and an indole isocyanate.
Topics: Cyclization; Hydrocarbons; Indoles; Isocyanates; Methane; Molecular Structure; Physostigmine; Sulfides | 2007 |
Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Humans; Indoles; Molecular Structure; Neurons; Physostigmine; Pyrroles | 2007 |
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.
Topics: Alzheimer Disease; Amyloid; Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Mice; Mice, Transgenic; Neuroglia; Neurons; Physostigmine; Stem Cell Transplantation; Stem Cells | 2007 |
Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.
Topics: Acetylcholinesterase; Binding Sites; Catalysis; Cholinesterase Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Models, Molecular; Molecular Structure; Mutation; Phenylcarbamates; Physostigmine; Protein Binding; Pyridostigmine Bromide; Rivastigmine; Structure-Activity Relationship | 2009 |
The perils of Alzheimer's drug development.
Topics: Alzheimer Disease; Animals; Biomedical Research; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Evaluation; Drug Industry; Humans; Observer Variation; Physostigmine; Selection Bias | 2009 |
Molybdenum-catalyzed asymmetric allylic alkylation of 3-alkyloxindoles: reaction development and applications.
Topics: Alkaloids; Alkylation; Catalysis; Heterocyclic Compounds, 4 or More Rings; Hydrocarbons, Halogenated; Indoles; Molecular Structure; Molybdenum; Oxindoles; Physostigmine; Stereoisomerism | 2011 |
Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cholinergic Antagonists; Cholinesterase Inhibitors; Discrimination, Psychological; Disease Models, Animal; Dogs; Donepezil; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Indans; Learning Disabilities; Male; Memory Disorders; Neuropsychological Tests; Odorants; Physostigmine; Piperidines; Scopolamine | 2011 |
Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Hippocampus; Hypoglycemic Agents; Infusions, Intraventricular; Lithium; Male; Memantine; Memory Disorders; Neuroprotective Agents; Physostigmine; Pioglitazone; Prefrontal Cortex; Rats; Rats, Wistar; Statistics, Nonparametric; Streptozocin; Thiazolidinediones | 2011 |
Synthesis of (+)-phenserine using an interrupted Fischer indolization reaction.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Indoles; Molecular Structure; Physostigmine; Pyrrolidines; Stereoisomerism | 2012 |
Acetylcholinesterase inhibition ameliorates deficits in motivational drive.
Topics: Anhedonia; Animals; Anxiety; Behavior, Animal; Body Weight; Cholinesterase Inhibitors; Chronic Disease; Drive; Habituation, Psychophysiologic; Hindlimb Suspension; Image Processing, Computer-Assisted; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Motivation; Nervous System; Phenotype; Physostigmine; Proto-Oncogene Proteins c-fos; Quinine; Restraint, Physical; Stress, Psychological; Swimming; Taste | 2012 |
Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Physostigmine; Research Design; Treatment Failure | 2013 |
Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Neuropathies; GPI-Linked Proteins; Hyperglycemia; Male; Mice; Motor Endplate; Muscle Weakness; Neuromuscular Junction Diseases; Physostigmine | 2012 |
Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
Topics: Acetylcholinesterase; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Molecular Structure; Physostigmine; Rats; Structure-Activity Relationship | 2012 |
Was phenserine a failure or were investigators mislead by methods?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Humans; MEDLINE; Physostigmine; Randomized Controlled Trials as Topic; Research Design; Treatment Failure | 2012 |
Editorial (hot topic:modulation of cholinergic system activity in neuronal and non-neuronal tissues: therapeutic implications).
Topics: Acetylcholine; Alzheimer Disease; Butyrylcholinesterase; Cholinergic Agents; Humans; Inflammation; MicroRNAs; Physostigmine | 2013 |
Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergi
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Humans; Interleukin-1beta; Physostigmine; Plaque, Amyloid; Receptors, Muscarinic; Receptors, Nicotinic; Stereoisomerism | 2013 |
Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doublecortin Protein; Drug Discovery; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Neural Stem Cells; Neurons; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Physostigmine; Stereoisomerism | 2013 |
Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell Proliferation; Disease Models, Animal; Doublecortin Protein; Female; Hippocampus; Interleukin-1beta; Male; Mice; Mice, Transgenic; Neuronal Plasticity; Neurons; Physostigmine; Plaque, Amyloid; Synapses; Tumor Necrosis Factor-alpha | 2013 |
Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease.
Topics: 5' Untranslated Regions; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Base Sequence; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Down Syndrome; Humans; Iron; Iron Regulatory Protein 1; Mice; Mice, Transgenic; Molecular Sequence Data; Neurons; Physostigmine; Protein Binding; Protein Biosynthesis; Response Elements; RNA, Messenger; Sequence Homology, Nucleic Acid | 2013 |
(-)-Phenserine attenuates soman-induced neuropathology.
Topics: Animals; Carrier Proteins; Chemical Warfare Agents; Cholinesterase Inhibitors; Gene Expression Regulation; Homer Scaffolding Proteins; Male; Physostigmine; Rats; Rats, Sprague-Dawley; Soman; Status Epilepticus | 2014 |
Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Carbamates; Cell Proliferation; Cognition; Doublecortin Protein; Female; Hippocampus; Humans; Male; Maze Learning; Memory; Mice; Nerve Regeneration; Neural Stem Cells; Neurogenesis; Nicotinic Agonists; Physostigmine; Quinuclidines; Stem Cell Transplantation | 2015 |
Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms.
Topics: Animals; Brain Concussion; Cholinergic Agents; Cholinesterase Inhibitors; Cognitive Dysfunction; Disease Models, Animal; Gene Expression Regulation; Glutamic Acid; Hippocampus; Humans; Lipid Peroxidation; Maze Learning; Mice; Neurons; Oxidative Stress; Physostigmine | 2016 |
(-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury.
Topics: Animals; Apoptosis; Brain Ischemia; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Glucose; Humans; Male; Neurons; Neuroprotective Agents; Physostigmine; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Stroke | 2017 |
Sequential combined Treatment of Pifithrin-α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke.
Topics: Animals; Atrophy; Benzothiazoles; Cell Differentiation; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cognition; Drug Therapy, Combination; Lateral Ventricles; Male; Mice, Inbred C57BL; Microtubule-Associated Proteins; Motor Activity; Neural Stem Cells; Neurogenesis; Physostigmine; Recovery of Function; Spheroids, Cellular; Stroke; Toluene | 2018 |
Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
Topics: Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Electrophorus; Kinetics; Molecular Docking Simulation; Physostigmine | 2019 |
(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.
Topics: Alzheimer Disease; Animals; Brain Concussion; Cell Death; Cerebral Cortex; Disease Models, Animal; Hippocampus; Mice; Mice, Transgenic; Neurons; Physostigmine | 2019 |
Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Down Syndrome; Endosomes; Humans; Mice; Neurons; Phenotype; Phosphorylation; Physostigmine | 2021 |
Mutasynthesis of Physostigmines in
Topics: Molecular Structure; Myxococcus xanthus; Physostigmine | 2021 |